Lantern Pharma (LTRN) 2026财年第二季度业绩电话会议：运营亏损收窄，LP-300与Open Medicine AI

核心要点

• 2026年第二季度运营亏损同比收窄25%至约350万美元，因研发费用下降42%至180万美元。
• 净亏损扩大至约710万美元（即每股0.57美元），主要反映了约360万美元的认股权证相关费用，其中包括重大的非现金公允价值调整。
• 截至2026年6月30日，现金、现金等价物及可交易证券总计约740万美元。Lantern Pharma在5月份通过注册直接发行募集了约440万美元的毛收益。
• 在LP-300 HARMONIC试验中，完成6个周期治疗的9名L858R患者的中位无进展生存期达到8.9个月。管理层强调该队列规模仍较小且属于探索性性质。
• 在与美国FDA举行C型会议后，Lantern围绕L858R患者优化了LP-300试验，将治疗周期从6个延长至最多8个，并转为单臂设计。
• Lantern于2026年8月将Open Medicine AI设立为一家独立的全资子公司。该业务拟独立筹集资金，同时Lantern保留对其药物项目的全部平台使用权限。

关键财务数据

截至2026年6月30日，Lantern拥有12,759,146股已发行普通股。该公司报告本季度在其按市价发行（ATM）售股安排下未发生任何活动。

业务与运营表现

LP-300与HARMONIC试验

Lantern正将HARMONIC试验的入组重点放在TKI治疗后出现进展的无吸烟史、携带L858R突变的非小细胞肺癌患者身上。

在完成6个周期的9名L858R患者中，中位无进展生存期为8.9个月，在5月11日数据截止时有3名患者尚未发生疾病进展。整个L858R队列的中位PFS为8.4个月，风险比为0.37，置信区间为0.15至0.89。

管理层还报告称，超过70%的L858R患者实现了目标病灶缩小，临床获益率为77%。部分缓解持续时间超过两年。据公司表示，4个周期与6个周期的安全性相当。

在与FDA举行C型会议后，Lantern将治疗延长至最多8个周期，并采用了旨在提高效率和降低成本的单臂设计。招募工作将在美国和台湾继续进行。

LP-184临床扩展

欧洲药品管理局批准了一项关于LP-184用于晚期膀胱癌的研究者发起期Ib/II期研究。这项在哥本哈根进行的包含39名患者的试验，将采用基于PTGR1过表达和DNA损伤修复缺陷的双生物标志物策略。

FDA还批准了LP-184单药治疗复发性或难治性三阴性乳腺癌的Ib/II期研究。Lantern预计该研究将在两个剂量队列中招募最多40名患者，随后进行Simon两阶段有效性评估。

Lantern收到了一项涵盖在卵巢癌、肝癌、肾癌和甲状腺癌中使用PTGR1、PTPN14和ASPH的三基因患者筛选方法的核准通知书。

LP-284与Starlight Therapeutics

LP-284继续在血液恶性肿瘤和成人软组织肉瘤中推进研发。该项目于2026年早些时候获得了孤儿药资格认定。

Starlight Therapeutics正在推进STAR-001（LP-184在脑癌领域的应用）。Lantern正与儿童肿瘤学联盟合作制定临床路径，并正在为罕见儿童脑肿瘤寻求同情用药方案。Starlight目前仍为Lantern的全资子公司，预计将寻求独立融资。

Open Medicine AI

Lantern于8月正式将Open Medicine AI（简称OMAI）设立为一家独立公司，并签署了商业许可协议。OMAI可商业化运营公司的多智能体AI系统，该系统集成了包括文献综合、药物化学、通路分析、数据策展、管线优先级排序及临床试验开发等领域的专业智能体。

Open Medicine AI目前由Lantern 100%持股。管理层表示，计划通过出让OMAI股权筹集资金，长期目标是使其成为一家单独上市的公司。Lantern预计将继续保持其最大股东之一的地位，并保留对其自身药物开发的完整平台使用权。

管理层展望

管理层预计，根据修改后的方案，未来四到六个月内将在美国和台湾增加约15至16名LP-300患者入组。关于现有队列的进一步更新可能会在2026年底前提供。

Lantern计划于9月中旬举行专门的Open Medicine AI信息沟通会，涵盖平台、市场机遇、路线图和商业模式。

获得额外资金仍是首要任务。公司表示，计划寻求融资、合作及其他机会，以延长运营资金支撑期。

风险与关注点

• 管理层强调，LP-300 L858R的结果来自样本量较小的探索性队列，尚未经统计学显著性验证。随着数据成熟，来自9名患者的中位PFS可能会发生变化。
• Lantern在本季度末拥有约740万美元的现金、现金等价物及可交易证券，并将寻求额外资金列为首要任务。
• Open Medicine AI需要额外资金来拓展业务并保持竞争力。其拟议的融资和长期独立上市仍属于管理层的目标，而非已完成的交易。
• 认股权证负债会计处理可能会对报告的净损益产生重大影响。第二季度业绩包含了约360万美元的认股权证相关费用，这主要是由非现金公允价值调整所致。
• 正如公司前瞻性声明披露所强调的那样，临床开发仍受制于试验结果、监管流程和市场竞争。

分析师问答亮点

管理层表示，修改后的LP-300方案在各试验中心的机构审查委员会批准已完成。招募工作预计将在8周期方案下恢复，接下来的15至16名患者预计将提供更有意义的疗效缓解数据。

关于Open Medicine AI，管理层强调了系统透明度、审计追踪以及企业用户调整工作流的能力，这些是其区别于早期AI药物开发工具的差异化优势。公司还表示大型制药公司对其产生了兴趣，但未透露商业收入或客户指标。

管理层将用户黏性描述为一旦使用平台的专业工具就“非常具有黏性”。公司正加大电子邮件推广力度，并使用专用访问码来提高知名度，包括在大型制药公司中。

关于股东价值，管理层表示Lantern正在评估将Open Medicine AI股票分派给Lantern股东的潜在途径。目前尚未确定具体结构或时间表。

业绩电话会议完整文字记录

完整财报电话会议逐字稿

管理层陈述

Operator

Earnings call. As a reminder, this call is being recorded, [Operator Instructions] A webcast replay of today's conference call will be available on our website at lanternpharma.com shortly after the call.

We issued a press release before market opened today, summarizing our financial results and progress across the company for the second quarter ended June 30, 2026. A copy of this release is available through our website at lanternpharma.com where you will also find a link to the slides management will be referencing on today's call.

We would like to remind everyone that remarks about future expectations, performance, estimates and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Lantern Pharma cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated.

A number of factors could cause actual results to differ materially from those indicated by forward-looking statements, including results of clinical trials and the impact of competition. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in our annual report on Form 10-K for the year ended December 31, 2025, which is on file with the SEC and available on our website.

Forward-looking statements made on this conference call are as of today, August 14, 2026, and Lantern Pharma does not intend to update any of these forward-looking statements to reflect events or circumstances that occur after today, unless required by law. The webcast replay of the conference call and webinar will be available on Lantern's website.

On today's webcast, we have Lantern Pharma's CEO, Panna Sharma; and CFO, David Margrave. Panna will start things off with an overview of Lantern's strategy and business model and highlight recent achievements in our operations, after which, David will discuss our financial results. This will be followed by some concluding comments from Panna, and then we'll open the call for Q&A.

I'd now like to turn the call over to Panna Sharma, President and CEO of Lantern Pharma. Panna, please go ahead.

Panna Sharma

Good morning, everyone, and thank you for joining us to discuss our second quarter 2026 results. As I've said before, AI and computationally driven approaches are now becoming central to have both large and emerging biopharma companies discover and develop drugs but also how they allocate the resources and think about staffing their scientific teams.

Today, we're at an inflection point that's actually accelerating, not just for Lantern, but for how science itself will be conducted. And we are watching it happen in real trials with real patients at Lantern. The golden age of artificial intelligence and medicine isn't beginning, it's actually accelerating. And this quarter, that idea has resulted in the development of a new company, Open Medicine AI. In August, we established Open Medicine AI as a separate company with commercial licenses and agreements with Lantern in place to take the AI data models to the next level.

I'll spend some real time on that today because I think it's the most consequential structural decision we've made since starting Lantern. But let me first walk you through what got us here, a clinical signal that sharpened into a defined patient population, a signal that was actually validated in using big data, a European regulatory clearance in a challenging recurrent cancer and allowed patent on a patient selection method for one of our most valuable assets, LP-184, and an FDA-cleared trial in triple-negative breast cancer that's moving toward launch. All of these were backed by numerous observations in our trials, the LP-300 trial, the LP-184 trial and even the LP-284 trial.

What those observations were is that the mechanistic insights gained during our preclinical work actually have real-world parallels. And they could be the basis for meaningful activity in actual cancer patients. The remainder of 2026 is a defining year for Lantern Pharma and especially as we launched in '27. We've achieved clinical validation across mobile programs while establishing the foundation for our next phase of growth in both of our engines, our drug development engine and also now our AI engine.

In addition, our midyear financial results reflect highly disciplined execution with a 25% reduction in total operating expenses year-over-year, even as we advanced multiple clinical programs through key inflection points and launched an entirely new company into one of the most promising and disruptive areas of AI, Medicine.

Our AI-driven clinical pipeline now encompasses multiple drug candidates across solid tumors, blood cancers and pediatric oncology with a combined annual market potential estimated at over $15 billion.

Let's start with our Phase II program, LP-300 and the HARMONIC trial in never-smokers non-small cell lung cancer who progressed after TKI therapy. We believe there's about 400,000 to 500,000 patients diagnosed globally each year that have no specific therapy aimed at never smokers that progressed after TKI. In Asia, it's about 35% to 40-plus percent of non-small cell lung cancer cases in U.S. and Europe, it's between 15% and 20%.

In June, we reported emerging data as the May 11 cutoff, and it shows something we didn't expect to see this clearly, but the benefit of LP-300 deepens the longer patients stay on it. Among L858R patients who completed 6 cycles, median progression-free survival reached 8.9 months. That's 9 patients, 3 of them hadn't progressed at analysis. Across the full cohort of L858R patients, median PFS was 8.4 months. The hazard ratio for that group was 0.37 with a confidence interval of 0.15 to 0.89.

So that means more than -- also more than 70% of the L858R patients saw a target lesion reduction and some of the response is sustained beyond 2 years. We've had a 77% clinical benefit rate, which is phenomenal for that line of therapy. I'll be direct. These are small exploratory cohorts, not powered for statistical significance yet. And a median from 9 patients can move up or down but what makes us take it very seriously is that a COGS regression controlling for race, gender TP53 status, which is very important, confirmed L858R as an independent predictor. This is not a demographic or a statistical artifact and safety was comparable between 4 and 6 cycles with no added toxicity from longer exposure.

So a drug that helps more, the longer you stay on it without costing you more in side effects is a drug worth extending, especially where there's no other great therapy for these patients. And that's actually the science and the data behind what we did next. We have a successful Type C meeting, where no objections were raised to our key proposed amendments. We've concentrated the enrollment now on the L858R patients. These patients actually tend to do worse on current therapy regimens. That's why we also think there's a great need. We've extended the treatment from now 6 to up to 8 cycles, and we've moved into a single-arm design, which should be more efficient and less costly.

The trial continues enrolling in the U.S. and Taiwan, and we've used this data set and other observations, of course, about the future of the program in active partnering discussions.

Let's talk a little bit about LP-184 this quarter. We've made several advances, all of which were driven by data and AI leverage methodologies. First, the EMA clearance. In July, we got clearance for an investigator-initiated Phase Ib/II trial in advanced bladder cancer. This is in Copenhagen, Denmark's national referral center for urologic cancers Rigshospitalet tout. And this is with Professor Rohrberg and Pappot. They're the coordinating investigators. This will be a 39 patient trial and very uniquely on 2 biomarker or a dual biomarker strategy, one on PTGR1 overexpression and then combining that with DNA damage repair deficiency. And we're hoping to enroll patients, very importantly, that our platform has predicted should respond and more importantly, have a mechanistic basis to be held by that drug.

Second major milestone is the 184 monotherapy in relapsed or refractory triple-negative breast cancer. That will be a Phase Ib/II trial that protocol has been FDA cleared and is now moving toward launch with a number of sites. We've also applied for grants for that trial for that study as well, which we're pretty excited about. This drug targets tumors of DNA damage repair alterations, homologous recombination deficiency or a genomic loss of heterozygosity. We expect to enroll up to 40 patients across 2 dose cohorts and will follow by a Simon 2-stage efficacy [indiscernible].

Third very important is that we received a notice of allowance in July, covering our 3 gene selection where we use 3 genes, PTGR1, PTP N-14 and AS PH for selection of patients most likely to respond to LP-184. We issued a notice of allowance in 4 tumors ovarian, liver, kidney and thyroid cancer. So that's a patent on the selection logic itself, which is one of the hardest parts of this to replicate and then map that directly to an incredible therapeutic intervention, where safety is known and mechanism is beginning to be more and more observable. This all built on our 63 patient trial that we did for 184. And now that we have a dose of 0.39 mg per kg and very importantly, what we saw in that trial is that we saw tumor reduction in patients that were carrying these DNA repair deficiency genes, CHEK2, ATM, BRCA 1, STK11, KEAP1. Those alterations conferred exceptional sensitivity to the drug.

Unlike conventional chemotherapies and other DNA damaging agents that indiscriminately target defining cells both LP-184 and 284 exploit specific genomic vulnerabilities in cancer cells. And that precision is a thread that runs parallel to both programs and which we expect to give our programs a meaningful advantage in their development. LP-284 continues in hematologic malignancies and in adult soft tissue cercocomas, where we've got orphan designation earlier this year. And Starlight briefly on the science, STAR-001, which is LP-184 in brain cancers. Our RADR platform identified that those particular brain tumors would be very sensitive if ERCC 3 was removed as a protein because that's involved in the repair mechanism.

Well, what we did is we characterize that with our group at Johns Hopkins that we collaborate with. And we're using spironolacton, which is already well characterized, safe and pediatric and adults. And it actually does exactly that. It degrades the ERCC3 protein and shuts down the repair route. And we've had great preclinical data, and now we're taking that into the clinic. We're taking it into disease designations where we have orphan designation and also rare pediatric such as ATRT, hepatoblastema, rhabdomyosarcoma and malignant rapidoid tumors. Bear in mind that each of these is independently eligible for a priority review voucher upon approval, and they recently transferred for $150 million to $200 million or more, and Lantern holds 4 of those.

On the pediatric program specifically, I'm very excited, and I want to give you an update. We're actively working with several pediatric oncology consortia to determine the best and most expeded path to bring these into a trial. As soon as possible. We've got 2 consortia that we're working with, and we'll have more data in this coming quarter.

We're also working closely to enable compassionate use for the drug, especially in some of these rare pediatric brain tumors where there's an exceptional need. Again, Starlight is 100% owned by Lantern. We expect to raise additional funding for it as a separate funding, holds its own INDs down, its own regulatory designations. And it's not just a program status. It's actually a way to monetize it independently of the rest of Lantern. And more importantly, it's a template. We're about to use that same template again this time with the underlying platform itself.

Now going back to Open Medicine. And this is, we believe, the structural news of the quarter. In August, we formally established Open Medicine, OMAI as a separate company, executed our Board-approved commercial licensing agreements. And more importantly, OMAI now can operate the multi-genic AICOscientists that we launched as with Zeta and use it in the commercial setting.

Here's the logic. Most people using AI drug development today, ask one model a question and get an answer. We now see that things are moving well beyond a single line of questioning for query. So we've built and orchestrated system. And this orchestra brings together specialized agents for literature synthesis, medicinal chemistry, pathway analysis, data curation, literature analysis, portfolio prioritization, clinical trial development and that -- then they challenge each other, and they pass information and ideas, and they cross-validate before delivering hardened results or ask the scientists or drug developer to get more engaged and ask them questions.

And this, we believe this multigenic non-monolithic model is really the standard infrastructure for specialized domains that are multi disciplinary, and we think it will be the standard infrastructure for drug discovery. And we think this is something that will be critical.

In addition to that, we believe that the computational biology model and the computational chemistry model that run deep and in their own large quantitative models is critical. And more importantly, it can generate publication quality results with a full audit trail. As a platform gets smarter and more users use it and data flows through it, each engagement for a user will feed the next. And this is exactly the kind of dynamic that deserved its own capital structure.

Clinical drug development and enterprise software are priced by different investors and different metrics held inside a clinical stage company, a software business may or may not get the credit for what it's worth because investors who price AI and software generally don't own clinical stage biotech and vice versa. That's the entire rationale for separating and racing forward with Open Medicine AI.

Open Medicine AI is 100% owned by Lantern today. It intends to raise capital at its own level in exchange for Open Medicine equity with the longer-term objective of becoming a separately listed company, Lantern expects to remain one of its largest shareholders.

So Lantern continues to retain the rights to the full access to the platform for our own drugs. And this changes nothing about this program's priority or timing. And we believe that the market there is much, much larger than just on early oncology companies like ourselves. Analysts project the market to reach about $10 billion by 2030, 2031. It was oncology is one of its largest segments.

Even doing my own bottoms-up analysis on companies in drug discovery, drug discovery technology, AI-enabled, I expect it to easily reach $9 billion to $10-plus billion by 2031. We'll host a dedicated informational call in mid-September on Open Medicine AI's market opportunity, platform, road map, commercial model. But putting all this together, a clinically validated platform with drugs and trials, a commercially accessible AI platform and software company with models and state-of-the-art tools and a drug pipeline that these all feed each other. You get a business model that extends well beyond just the clinical assets. We think it's a very powerful complement to have both of these engines, an AI engine that can be separated and power dozens of companies and drug assets that are going after meaningful, challenging rare and aggressive diseases. And we think these are very complementary.

The AI tools and services, we think can grow to being several hundred million dollars in stand-alone as part of this larger $10 billion market. We think a nice chunk of that $10 billion market will be agentic in nature, and Open Medicine will have the real chance at driving a significant piece of that. So these are 2 great growth engines in the company.

And I'll let David talk a little bit -- David Margrave, to discuss our financials or key metrics and also dig into the details behind the noncash expenses that are related to warrants that drive a higher net operating loss than what's actually underneath the hood.

So David, I'll turn it over to you.

David Margrave

Thank you, Panna, and good morning, everyone. I'll now share some financial highlights from our second quarter ended June 30, 2026. Before getting into the details of the quarter, I want to note that this quarter was different from prior quarters because we had a substantial noncash expense related to the issuance of warrants in connection with our May financing transaction and the way those warrants are treated for accounting purposes. I'll discuss this topic in detail later in my discussion.

Cash, cash equivalents and marketable securities were approximately $7.4 million at June 30, '26, consisting of approximately $6.7 million in cash and cash equivalents and approximately $0.7 million in marketable securities compared to approximately $10.1 million in cash, cash equivalents and marketable securities as of December 31, 2025.

Funding received during the second quarter of 2026 consisted of approximately $4.4 million in gross proceeds from our registered direct offering that closed on May 14, 2026. Additional funding is a top priority, and we intend to pursue additional capital raises, collaborations and other opportunities to extend our operating runway.

R&D expenses were approximately $1.8 million for the 3 months ended June 30, 2026 compared to approximately $3.1 million for the 3 months ended June 30, 2025. This was a decrease of approximately $1.3 million or 42%. The decrease was primarily attributable to reductions of approximately $1 million in research studies and materials expenses relating to the conduct of our clinical trials and decreases of approximately $0.3 million in salaries and benefit expenses.

G&A expenses were approximately $1.7 million for the 3 months ended June 30, 2026 compared to approximately $1.6 million for the 3 months ended June 30, 2025. This was an increase of approximately $0.13 million or 8%. The increase was primarily attributable to increases in business development and investor relations expenses of approximately $0.36 million and salaries and benefit expense increases of approximately $0.14 million, offset in part by decreases in other professional fees of approximately $0.35 million.

Loss from operations was approximately $3.5 million for the 3 months ended June 30, 2026 compared to a loss from operations of approximately $4.7 million for the 3 months ended June 30, 2025, representing a decrease of approximately 25%.

In connection with our May 2026 registered direct offering, in which we raised approximately $4.4 million in gross proceeds, the company issued investor warrants to purchase up to 2,135,923 shares of common stock at an exercise price of $2.27 per share and placement agent warrants to purchase up to 106,796 shares of common stock at an exercise price of $2.75 million per share. These warrants are accounted for as liabilities due to a settlement feature that may be triggered in the event of a fundamental transaction.

During the 3 months ended June 30, 2026, the company recorded an aggregate of approximately $3.6 million of expense related to these warrants. The main component of this was noncash expense arising from an increase in the fair value of the warrants that was driven primarily by a substantial increase in the company's stock price between the May 14, 2026 warrant issuance date and June 30, 2026. Other components related to warrant expense were loss on issuance of the warrants and warrant issuance costs. After including the noncash and other items related to warrants our net loss was approximately $7.1 million or $0.57 per share for the 3 months ended June 30, 2026 compared to a net loss of approximately $4.3 million or $0.40 per share for the 3 months ended June 30, 2025.

For the 6 months ended June 30, 2026, our net loss was approximately $10.4 million or $0.88 per share compared to a net loss of approximately $8.9 million or $0.82 per share for the 6 months ended June 30, 2025.

From a capitalization standpoint, as of June 30, 2026, the company had 12,759,146 shares of common stock outstanding. And as we described, in May 26, we closed a registered direct offering and concurrent private placement, comprising 1,454,175 shares of common stock, prefunded warrants to purchase up to 681,748 shares of common stock, investor warrants to purchase up to 2,135,923 shares of common stock at an exercise price of $2.27 per share and placement agent warrants to purchase up to 106,796 shares of common stock at an exercise price of $2.55 per share. There was no activity under our ATM sales facility during the 3 months ended June 30, 2026. I'll now turn the call back over to Panna for an additional update on our programs and operations. Panna

Panna Sharma

Thank you, David. So 2 closing points. First, the number I want all of you to remember is that we advanced programs from AI-derived in science to first-in-human clinical trials in a time line under 3 years and roughly 2 to 3 years at approximately $2 million to $3 million each. The industry norm to reach that same point and is 5 to 10 years is at 25 to 100. We have 3 molecules in clinical trials of dosed over 100 patients and at the same time, have been able to advance an AI platform that's launching commercially. Those numbers are not a marketing claim. It's actually our operating model, and it's a key part of our core advantage. Secondly, what we now have structurally that we didn't have just in April is a lung cancer trial refined around a specific patient population, L858R mutations. We have European clearance for a dual biomarker trial, which will be led by investigators in Denmark and a challenging recurrent bladder cancer setting. And FDA cleared a second trial in triple-negative breast cancer post-PARP refractory patients moving toward launch and an AI and software company with executed licenses, multiple engineering centers and a growing user base. As David just walked you through, we actually did all that, while our actual operating losses or loss from operations were down approximately 25% year-over-year. And we did all of this while continuing to advance both engines of growth. We believe that's a really important and smart way to build, and that's the argument for continuing to operate this way. We're not just building better tools. We're reimagining what's possible in precision oncology and building the tools to support it. We believe this will be the standard for the rest of the industry. And more importantly, it's the platform that we think will be positioned to scale. I want to thank our team, our investigators and our shareholders as we light our way through precision oncology solutions, and we expect to have a lot of great additional results over the coming quarters. And I want to especially thank our own team here at Lantern PAUSE especially a longtime member of our team, who's moving on to a new leadership opportunity in media and technology after 5 years with us. PAUSE Five years of building this company's brand, voice communications and also being an amazing colleague. So thank you very much. With that, I'd like to now open the call to questions. You can type your question using the QA tool, or raise your hand, and we'll try to unmute your line and repeat your question. So any questions with the remaining time that we have.

Operator

Michael should be unmuted. PAUSE SP578731125 Can you hear me? PAUSE. Yes. PAUSE SP-2 Two questions, Panna. -- 1 on LP-300 and then the other on OMI. Just on 300 PAUSE -- can you talk about what -- where are you in the data analysis? It's obviously nice to see the PFS stretching a little bit more. But how PAUSE matures this data set? Will it mature further? When do you plan to update us again? And any other PAUSE well, and then the next question related to that is now that you've got the protocol amendment in place, have any patients been PAUSE enrolled under the new protocol. PAUSE. All right. Let's go a lot of questions. But we -- once we got the product -- once we had sufficient confidence that the protocol would be I mean it in the data was trending that way.

We wanted to get the new IRBs approved at all the sites, and that's all been done now. So we expect enrollment to resume under the new 8 cycles, which is important. We think that will extend durability and maybe even deep in response. So we expect to be enrolling patients in Taiwan to the U.S., specifically under the new amended protocol. We hope to expect another 15, 16 patients that will give us meaningful data, and we expect to enroll those over the next 4 to 6 months, both in the U.S. and Taiwan. That's the initial focus.

分析师问答

Unknown Analyst

Will there be any other updates coming on the current cohort?

Panna Sharma

We may have an update toward the end of the year. I mean, I think other than just extending PFS PAUSE we're really relying on the next batch of patients coming in to see what we would kind of responses that we continue getting.

Unknown Analyst

Okay. Very good. And then just on open medicine. Can you talk about -- I think most of us that come from sort of therapeutics background or not, experts. Most of the technology is a black box because the companies like in silico medicine and others don't open their mono to see what's actually operating internally. Maybe you can help us understand what your system looks like or how it compares, how should we think about it in the context of the other tools that are out there that the pharma industry seems to be taking advantage of.

Panna Sharma

Yes. So there's actually been working on something for our mid-September webinar, but the AI cycle in drug development, we're kind of on our fourth cycle. I mean if you go back to early days of supercomputers and molecular modeling and large installed bases was kind of like the first wave limited limited compute resource, but infrastructure heavy. We're almost at the opposite end of that now, where we have almost limitless compute resource and infrastructure install super light. And there are 2 ways caught in between that. And we really didn't have the capability to kind of get the transparency that you would want real time until after an algorithm was run.

And oftentimes, those algorithms would take days or weekends or long term. But now those can be done in seconds. And so you can get real-time what is the process that happened. We also didn't have the software and tools to do large-scale algorithm mapping and analysis because it was just extra overhead. But now we have the ability to do that. So we get transparency that we didn't have that was a luxury in the past. Now it's commonplace and people expect it. And so a lot of the large-scale AI providers, including the anthropics and open AIs of the world, and even to some extent, KEMET and Deep Seek have made some levels of transparency to how the system operates more expected. PAUSE And that is something that we rest on the shoulders of. We can do it very differently. And so that's a platform that we've built.

And more importantly, what you see it's the transparency you as an enterprise user or end user, can actually tweak it and alter it, and that just didn't exist before. So yes, we're in a different way of how AI I expect -- and I'll mention this in the webinar in September is that the people who are going to be hit the hardest are going to be 2. Number one, people who provide professional knowledge labor basically. And then second, it's going to be the existing installed base of software providers into pharma. Those days of going in being able to charge $100,000, $500,000, $300,000 for some very, very specific functionality of an installed base. Those days are going to be gone. They're all going to go to providers like open medicine. And also, you're not going to hire teams of buying from aticians and teams of data analytics people. It's just we can do all that now in the cloud with 1 smart engineer, data science person. And you can launch swarms of people, swarms of agents doing this work for you, and that's especially what we've proven with open medicine.

So I think that's the future. And I think that's where leading-edge providers like Cloud Science and others are going toward. People are going to expect greater transparency. And if you really want to democratize the development of drugs, you're going to have to be able to allow people to go to a URL to go to an app and start their inquiry. And that's exactly what we see open medicine playing is a new category that just hasn't been valued in price. I'm writing a piece you'll see by mid-September, and it's called the deflation of discovery and the birth of a new category. And that specifically talks to Agentic AI and drug development and drug discovery.

Another question. I'll take -- sorry -- so someone's asking an interest with data from large pharma. The quick answer is, yes, we've got a lot of pharma companies, both biologic groups as whether it's small molecule groups. We've had some -- had several calls with us, some visit. So the answer is yes. Large pharma is definitely interested. This is something that they're all evaluating cutting deals on looking at and large pharma will have to partner with Agentic AI to make it commonplace. I mean it's transforming the economics of early development and also late-stage development.

So yes, very much increasing interest. The more marketing, more dollars we can put behind driving awareness of open medicine and with Zeta, the more I expect. The one thing that we've seen that has been solid is that once we put the tool in front of people, it gets very sticky. So yes, thank you. Take another important question.

Let's see if we can do this one live. We're trying to live I don't know go ahead and get to live. I can also we don't want to do it live.

I can read it also if you don't want to do it live.

So this is another question. is our models, we expect will be standards in computational biology and drug development. What are you doing to ensure that and that other competitors don't copy your methods? Well, I -- first of all, everyone will copy one or another. And that's part of putting open medicine separately is to allow it to move faster, further and have its own independent balance sheet. To ensure that you always stay 1 or 2 steps ahead. Companies -- there are definitely companies that have more capital, more capital doesn't necessarily mean you're going to be the surviving entity. You can look at any industry and capital efficiency is important long term, which we've proven to be very capital efficient at. We're at a point where it needs to be a separate entity and raise its own capital to stay ahead of the curve.

The things that we're doing in addition to continuing to train our models and try to grow intelligently using our center in Bangalore, India. Those are things that we're doing. We're also constantly benchmarking like we did with our BBB algorithm like we're doing with our bio computational tools. We're trying to pick some of the toughest challenges and go deep as opposed to go abroad. And that's one of the things that were big components of is going deep in certain categories versus broad across all of science. I don't think we ever would have claimed, hey, we're going to be cloud science and do all of science. I think that just makes no sense to me.

You can pick specific categories like rare cancers, specific areas like biocomputational tools, specific problems like blood brain barrier or penetration into any tissue type and do it and resolve it really, really well. So we're going to go after certain diseases that we think require that kind of depth and then march forward in that fashion. But yes, capital, no doubt, more capital is needed to drive that.

Let's go ahead and get to the next question. Yes, let's go to Baird and Red ship team. Maybe we can answer that 1 live Bard and Red ship team, if you guys want to ask your question live. They can ask their question live. You have to read the question.

Okay. All right. Dave, asking a question on what does adoption and feedback look like? The adoption is very sticky. Like I said before, once we get it in front of users. We were taking certain measures to make sure that users get the benefit of the full platform. We've introduced a new code called Wood Zeta 14 that people can sign up for and get the full professional addition, people who play the professional edition, specially generative chemistry, biocomputational tools, the investigator mode, it tends to be very, very sticky. So that's exciting news. Key is getting them to that point. So we're also beginning to implement some more aggressive e-mail campaigns to drive the awareness and specialized codes for certain larger pharma companies. But yes, great question. Okay. Another question is

Anonymous. What would you contemplate the biggest benefit of the open medicine spin-out will be for shareholders?

Well, Lantern owns 100% of open medicine today. We think it's poised to be very disruptive, disruptive companies are usually valued -- can be valued higher, and we're going to raise capital. Matter will continue being the largest shareholder, we think, for a while. PAUSE -- and we may explore ways to distribute those -- the underlying shares to all shareholders and lanterns. So those are things that we're talking about and potentially distribution of the shares of open medicine to all Lantern shareholders. Again, we're having discussions. We're looking at the most efficient ways to do that, but I expect Lantern shareholders to continue being beneficiaries of that asset as we monetize it, both in private financings and very importantly, as it potentially goes into an exchange public exchange.

Okay. I think we're coming up to almost 45 minutes into the call. And we look forward to answering questions and one-on-ones as it continues. I know we have a couple of requests for some one-on-one follow-up meetings. We'll take those as well. And thank you, guys, for participating. I want to thank all the Lantern investors, people who are interested, and I look forward to giving you guys more updates as the year continues. Thank you, and thank you again to our team as well.

David Margrave

Thanks a lot.